BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
Recruiting · NCT05922761 · Registry updated 2026-06-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP) | Bronchiolitis Obliterans, bronchial disorder, bronchiolitis, bronchiolitis obliterans syndrome, bronchitis, cryptogenic organizing pneumonia, graft versus host disease, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder | Recruiting | Phase 2 | 2026-06-10 | NCT05922761 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Dana-Farber Cancer Institute | 324 |
| National Heart, Lung, and Blood Institute (NHLBI) | 791 |
| Sanofi | 254 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Boston Children's Hospital | Boston | United States | 20 |
| Brigham and Women's Hospital | Boston | United States | 60 |
| Dana-Farber Cancer Institute | Boston | United States | 68 |
| Fred Hutchinson Cancer Center | Seattle | United States | 250 |
| Stanford University School of Medicine | Stanford | United States | 46 |
| University of Michigan | Ann Arbor | United States | 538 |